Denis Bragin

Scientific Advisor

EXPERIENCE

Dr. Bragin holds a BS/MS in Biology/Biochemistry and a PhD in Biophysics, with over 20 years of experience in translational neuroscience research. Collaborating with Drs. Nemoto and Kameneva, Dr. Bragin was the first to demonstrate the beneficial effects of Drag Reducing Polymers in treating conditions associated with brain ischemia. This groundbreaking discovery laid the foundation for the patent applications that Dr. Bragin and his colleagues successfully filed and secured (9,763,975 and 10,792,304).​

WHY WERE YOU SELECTED FOR YOUR CURRENT ROLE AT SHEARIT, LLC

Translational Research Expertise

PROUDEST ACCOMPLISHMENT

Demonstrated, for the first time, the beneficial effects of Drag Reducing Polymers, lately trademarked as Lamiflo™, in treating conditions associated with brain ischemia and peripheral organs hypoperfusion (traumatic brain injury, ischemic stroke, diabetes mellitus, hemorrhagic and septic shock, and Alzheimer’s Disease).

COMMUNITY INVOLVEMENT & PROFESSIONAL MEMBERSHIP

  • International Society of Cerebral Blood Flow and Metabolism
  • International Society of Oxygen Transport to Tissue
  • National Neurotrauma Society
  • Critical Care Medicine Society
  • American Heart Association (Stroke Council)
  • Society for Optics & Photonics
  • Associate Editor, Frontiers in Neurosurgery
  • Review Editor, Frontiers in Neurotrauma

PROFESSIONAL AFFILIATIONS & CREDENTIALS

  • Associate Professor of Translational Neuroscience, Lovelace Biomedical Research Institute, Albuquerque, NM
  • Adjunct Associate Professor, Department of Neurology, University of New Mexico School of Medicine, Albuquerque, NM

AWARDS & HONORS

2015 — Fellow of the American Heart Association, Stroke Council (FAHA)